Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

a study on Diabetes Diabetes Type 1

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Laya Ekhlaspour, MD (ucsf)
Headshot of Laya Ekhlaspour
Laya Ekhlaspour

Description

Summary

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

Official Title

Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study

Keywords

Type 1 Diabetes, GLP1-RA, SGLT2i, Type 1 Diabetes Mellitus

Eligibility

You can join if…

Open to people ages 18 years and up

  • Adults ≥18 years of age
  • Clinical diagnosis of T1D
  • GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
  • Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
  • Willing and able to provide informed consent

You CAN'T join if...

  • No exclusion criteria other than those not meeting inclusion criteria above

Locations

  • University of California, San Francisco (UCSF) accepting new patients
    San Francisco California 94158 United States
  • Hoag Memorial Hospital accepting new patients
    Newport Beach California 92663 United States

Lead Scientist at University of California Health

  • Laya Ekhlaspour, MD (ucsf)
    I am a physician-scientist and an assistant Professor of Pediatrics at the University of California, San Francisco, and my research is focused on the use of technology in children with type 1 diabetes.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Indiana University
ID
NCT07676565
Study Type
Observational [Patient Registry]
Participants
Expecting 300 study participants
Last Updated
Contact us about this trial